Rigel Pharmaceuticals | RIGL - Net Income


Rigel Pharmaceuticals reported $12.42M in Net Income for its fiscal quarter ending in September of 2024.





Net Income Change Date
Agenus USD 39.17M 49.8M Mar/2026
Amgen USD 3.86B 1.49B Sep/2026
Anika Therapeutics USD 292K 2.62M Dec/2025
Arrowhead Research USD -194.28M 61.55M Jun/2026
AstraZeneca USD 3.12B 610M Sep/2026
BioMarin Pharmaceutical USD -122.83M 167.59M Sep/2026
Bristol-Myers Squibb USD 2.16B 1.16B Sep/2026
Celldex Therapeutics USD -75.56M 2.05M Sep/2026
Daiichi Sankyo JPY 82.9B 14.26B Sep/2026
Eli Lilly USD 7.1B 301M Jun/2026
Halozyme Therapeutics USD 247.05M 17.14M Sep/2026
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Ionis Pharmaceuticals USD -87M 27.65M Sep/2026
Karyopharm Therapeutics USD -22.39M 79.81M Mar/2026
Ligand Pharmaceuticals USD -28.48M 76.99M Sep/2026
MacroGenics USD 19.52M 56.29M Jun/2026
Neurocrine Biosciences USD 206.5M 62.1M Sep/2026
Pfizer USD 3.24B 3.49B Sep/2026
Regeneron Pharmaceuticals USD 1.3B 569.7M Jun/2026
Rigel Pharmaceuticals USD 12.42M 13.45M Sep/2024
Sangamo BioSciences USD -36.13M 12.96M Jun/2024
Ultragenyx Pharmaceutical USD -118M 26M Sep/2026
Veracyte USD 31.5M 6.01M Sep/2026